Placebo for JNJ-56136379

DRUG2 trials

Sponsors

Janssen Sciences Ireland UC

Conditions

Hepatitis B, Chronic

Phase 2

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

CompletedNCT03982186

Janssen Sciences Ireland UCHepatitis B, Chronic

Start: 2019-08-01End: 2022-04-26Updated: 2025-02-04

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

CompletedNCT04129554

Janssen Sciences Ireland UCHepatitis B, Chronic

Start: 2019-11-06End: 2022-06-09Updated: 2025-02-04

Related Papers

Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trials.

2025-10-09

Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.

2025-02-261 citations

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Journal of Hepatology2024-04-0534 citations

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

2023-07-1055 citations